{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    17,
    18,
    19,
    20,
    21,
    22
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Long-term Survival Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.8",
        "sectionTitle": "Final CSR Analysis and Long-term Survival Follow-up",
        "description": "Defines the long-term survival follow-up procedures."
      },
      {
        "id": "ref_2",
        "name": "Final OS Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.9",
        "sectionTitle": "Final OS analysis Until End of Study",
        "description": "Defines the final OS analysis cut-off."
      },
      {
        "id": "ref_3",
        "name": "End of Study Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "17.9.1",
        "sectionTitle": "Final OS Analysis/End of Study",
        "description": "Defines the end of study parameters."
      },
      {
        "id": "ref_4",
        "name": "Prohibited Therapies Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Prohibited Therapies",
        "description": "Reference for managing symptoms while avoiding prohibited therapies."
      },
      {
        "id": "ref_5",
        "name": "Biomarker Testing Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "16.2.5",
        "sectionTitle": "Long-Term Retention of Samples for Additional Future Research",
        "description": "Reference for additional biomarker testing at later time points."
      },
      {
        "id": "ref_6",
        "name": "Subsequent Therapies Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4",
        "sectionTitle": "Subsequent Therapies",
        "description": "Reference for subjects who discontinue study treatment for reasons other than disease progression."
      },
      {
        "id": "ref_7",
        "name": "IMWG Progression Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "International Uniform Response Criteria Consensus Recommendations",
        "description": "Criteria for confirming disease progression."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries. The term 'sponsor' represents these various legal entities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "After Study MMY3008 transitions to long-term survival follow-up, an end-of-treatment visit is no longer required.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Figure 2",
        "pageNumber": 9
      },
      {
        "id": "annot_3",
        "text": "Pharmacokinetic and anti-daratumumab antibody sampling is no longer required for subjects in Treatment Arm B who remain on daratumumab IV therapy.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time & Events Schedule Overview",
        "pageNumber": 12
      },
      {
        "id": "annot_4",
        "text": "Immunohistochemistry or immunofluorescence or 2- to 4-color flow cytometry are acceptable methods to evaluate plasma cell clonality.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Bone Marrow Testing Table",
        "pageNumber": 19
      },
      {
        "id": "annot_5",
        "text": "Trained study staff at the clinic should be prepared to intervene in case of any infusion-related reactions occurring, and resources necessary for resuscitation must be available at the bedside.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "6.1.5 Management of Infusion-related Reactions",
        "pageNumber": 13
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "12.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-07-20",
        "description": "To define the clinical cut-off for the final CSR analysis and transition to long-term survival follow-up.",
        "amendmentNumber": "Amendment 9"
      },
      {
        "id": "ver_2",
        "versionNumber": "N/A",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-04-03",
        "description": "To provide flexibility during the COVID-19 pandemic, including the option to switch to subcutaneous daratumumab.",
        "amendmentNumber": "Amendment 8"
      },
      {
        "id": "ver_3",
        "versionNumber": "N/A",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-01-17",
        "description": "Clarifications to study conduct and alignment with updates in all daratumumab protocols.",
        "amendmentNumber": "Amendment 7"
      },
      {
        "id": "ver_4",
        "versionNumber": "N/A",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-06-12",
        "description": "Response to identification of a new important risk (hepatitis B virus reactivation).",
        "amendmentNumber": "Amendment 6"
      },
      {
        "id": "ver_5",
        "versionNumber": "N/A",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-01-15",
        "description": "Allowing subjects in Arm A access to daratumumab after sponsor confirmation of disease progression.",
        "amendmentNumber": "Amendment 5"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}